Literature DB >> 21645643

Intraperitoneal photodynamic therapy mediated by a fullerene in a mouse model of abdominal dissemination of colon adenocarcinoma.

Pawel Mroz1, Yumin Xia, Daisuke Asanuma, Aaron Konopko, Timur Zhiyentayev, Ying-Ying Huang, Sulbha K Sharma, Tianhong Dai, Usman J Khan, Tim Wharton, Michael R Hamblin.   

Abstract

Functionalized fullerenes represent a new class of photosensitizer (PS) that is being investigated for photodynamic therapy (PDT) of various diseases, including cancer. We tested the hypothesis that fullerenes could be used to mediate PDT of intraperitoneal (IP) carcinomatosis in a mouse model. In humans this form of cancer responds poorly to standard treatment and manifests as a thin covering of tumor nodules on intestines and on other abdominal organs. We used a colon adenocarcinoma cell line (CT26) stably expressing luciferase to allow monitoring of IP tumor burden in BALB/c mice by noninvasive real-time optical imaging using a sensitive low-light camera. IP injection of a preparation of N-methylpyrrolidinium-fullerene formulated in Cremophor-EL micelles, followed by white-light illumination delivered through the peritoneal wall (after creation of a skin flap), produced a statistically significant reduction in bioluminescence and a survival advantage in mice. FROM THE CLINICAL EDITOR: This team of investigators report on functionalized fullerenes, to be used as photosensitizer for photodynamic therapy and demonstrate the efficacy of this method in an intraperitoneal carcinomatosis mouse model.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21645643      PMCID: PMC3183379          DOI: 10.1016/j.nano.2011.04.007

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  44 in total

1.  Photo-induced reactive oxygen species generation by different water-soluble fullerenes (C) and their cytotoxicity in human keratinocytes.

Authors:  Baozhong Zhao; Piotr J Bilski; Yu-Ying He; Li Feng; Colin F Chignell
Journal:  Photochem Photobiol       Date:  2008-04-09       Impact factor: 3.421

2.  Conjugates of daidzein-alliinase as a targeted pro-drug enzyme system against ovarian carcinoma.

Authors:  Elena Appel; Aharon Rabinkov; Michal Neeman; Fortune Kohen; David Mirelman
Journal:  J Drug Target       Date:  2010-08-03       Impact factor: 5.121

Review 3.  Fullerenes: from carbon to nanomedicine.

Authors:  Pooja Chawla; Viney Chawla; Radhika Maheshwari; Shubhini A Saraf; Shailendra K Saraf
Journal:  Mini Rev Med Chem       Date:  2010-07       Impact factor: 3.862

4.  Photodynamic therapy with a cationic functionalized fullerene rescues mice from fatal wound infections.

Authors:  Zongshun Lu; Tianhong Dai; Liyi Huang; Divya B Kurup; George P Tegos; Ashlee Jahnke; Tim Wharton; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2010-12       Impact factor: 5.307

5.  Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.

Authors:  Vincent Boudousq; Stéphanie Ricaud; Véronique Garambois; Caroline Bascoul-Mollevi; Samir Boutaleb; Muriel Busson; François Quenet; Pierre-Emmanuel Colombo; Manuel Bardiès; Pierre-Olivier Kotzki; Isabelle Navarro-Teulon; André Pèlegrin; Jean-Pierre Pouget
Journal:  J Nucl Med       Date:  2010-10-18       Impact factor: 10.057

6.  Active oxygen species generated from photoexcited fullerene (C60) as potential medicines: O2-* versus 1O2.

Authors:  Yoko Yamakoshi; Naoki Umezawa; Akemi Ryu; Kumi Arakane; Naoki Miyata; Yukihiro Goda; Toshiki Masumizu; Tetsuo Nagano
Journal:  J Am Chem Soc       Date:  2003-10-22       Impact factor: 15.419

7.  Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model.

Authors:  K L Molpus; D Kato; M R Hamblin; L Lilge; M Bamberg; T Hasan
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

8.  Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging.

Authors:  Masafumi Toyoshima; Yoshinori Tanaka; Mitsuyo Matumoto; Miyuki Yamazaki; Satoru Nagase; Kazuo Sugamura; Nobuo Yaegashi
Journal:  Luminescence       Date:  2009 Sep-Oct       Impact factor: 2.464

9.  Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism.

Authors:  Pawel Mroz; Anna Pawlak; Minahil Satti; Haeryeon Lee; Tim Wharton; Hariprasad Gali; Tadeusz Sarna; Michael R Hamblin
Journal:  Free Radic Biol Med       Date:  2007-05-10       Impact factor: 7.376

10.  Magnetic field effects on the photohemolysis of human erythrocytes by ketoprofen and protoporphyrin IX.

Authors:  C F Chignell; R H Sik
Journal:  Photochem Photobiol       Date:  1995-07       Impact factor: 3.421

View more
  20 in total

1.  Photodynamic therapy with fullerenes in vivo: reality or a dream?

Authors:  Sulbha K Sharma; Long Y Chiang; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2011-12       Impact factor: 5.307

2.  Can nanotechnology potentiate photodynamic therapy?

Authors:  Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Hoon Chung; Anastasia Yaroslavsky; Maria Garcia-Diaz; Julie Chang; Long Y Chiang; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2012-03       Impact factor: 7.848

3.  Photodynamic Therapy with Hexa(sulfo-n-butyl)[60]Fullerene Against Sarcoma In Vitro and In Vivo.

Authors:  Chi Yu; Pinar Avci; Taizoon Canteenwala; Long Y Chiang; Bao J Chen; Michael R Hamblin
Journal:  J Nanosci Nanotechnol       Date:  2016-01

Review 4.  Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.

Authors:  Sarah A Engelberth; Nadine Hempel; Magnus Bergkvist
Journal:  Crit Rev Oncog       Date:  2014

Review 5.  New photosensitizers for photodynamic therapy.

Authors:  Heidi Abrahamse; Michael R Hamblin
Journal:  Biochem J       Date:  2016-02-15       Impact factor: 3.857

6.  Type I and Type II mechanisms of antimicrobial photodynamic therapy: an in vitro study on gram-negative and gram-positive bacteria.

Authors:  Liyi Huang; Yi Xuan; Yuichiro Koide; Timur Zhiyentayev; Masamitsu Tanaka; Michael R Hamblin
Journal:  Lasers Surg Med       Date:  2012-07-03       Impact factor: 4.025

Review 7.  Functionalized fullerenes in photodynamic therapy.

Authors:  Ying-Ying Huang; Sulbha K Sharma; Rui Yin; Tanupriya Agrawal; Long Y Chiang; Michael R Hamblin
Journal:  J Biomed Nanotechnol       Date:  2014-09       Impact factor: 4.099

8.  Synthesis and photodynamic effect of new highly photostable decacationically armed [60]- and [70]fullerene decaiodide monoadducts to target pathogenic bacteria and cancer cells.

Authors:  Min Wang; Liyi Huang; Sulbha K Sharma; Seaho Jeon; Sammaiah Thota; Felipe F Sperandio; Suhasini Nayka; Julie Chang; Michael R Hamblin; Long Y Chiang
Journal:  J Med Chem       Date:  2012-04-26       Impact factor: 7.446

9.  Nanotechnology for photodynamic therapy: a perspective from the Laboratory of Dr. Michael R. Hamblin in the Wellman Center for Photomedicine at Massachusetts General Hospital and Harvard Medical School.

Authors:  Michael R Hamblin; Long Y Chiang; Shanmugamurthy Lakshmanan; Ying-Ying Huang; Maria Garcia-Diaz; Mahdi Karimi; Alessandra Nara de Souza Rastelli; Rakkiyappan Chandran
Journal:  Nanotechnol Rev       Date:  2015-08-07       Impact factor: 7.848

10.  Fullerenes as photosensitizers in photodynamic therapy: pros and cons.

Authors:  Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2018-07-25       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.